BR112013001577A2 - conjugados de carboidrato e dihidorxiclorina e clorina <225>-funcionalizada e respectivos usos e método para eliminar microorganismos em ambiente de paciente real - Google Patents

conjugados de carboidrato e dihidorxiclorina e clorina <225>-funcionalizada e respectivos usos e método para eliminar microorganismos em ambiente de paciente real

Info

Publication number
BR112013001577A2
BR112013001577A2 BR112013001577A BR112013001577A BR112013001577A2 BR 112013001577 A2 BR112013001577 A2 BR 112013001577A2 BR 112013001577 A BR112013001577 A BR 112013001577A BR 112013001577 A BR112013001577 A BR 112013001577A BR 112013001577 A2 BR112013001577 A2 BR 112013001577A2
Authority
BR
Brazil
Prior art keywords
conjugates
carbohydrate
dihydroxychlorine
real patient
patient environment
Prior art date
Application number
BR112013001577A
Other languages
English (en)
Other versions
BR112013001577B1 (pt
Inventor
Wiehe Arno
Gitter Burkhard
B W Stark Christian
Aicher Daniel
Albrecht Volker
Original Assignee
Biolitec Pharma Marketing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolitec Pharma Marketing Ltd filed Critical Biolitec Pharma Marketing Ltd
Priority claimed from PCT/US2011/045063 external-priority patent/WO2013015774A1/en
Publication of BR112013001577A2 publication Critical patent/BR112013001577A2/pt
Publication of BR112013001577B1 publication Critical patent/BR112013001577B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

conjugados de carboidrato e dihidorxiclorina e clorina <225>-funcionalizada e respectivos usos e método para eliminar microorganismos em ambiente de paciente real. são proporcionados conjugados moleculares antimicrobianos para o tratamento e prevenção de doenças infecciosas causadas por microorganismos patogênicos em pessoas humanas e em animais. a chave para estes conjugados é conectar dihidroxiclorinas ou clorinas <225>-funcionalizadas a grupamentos de carboidratos. estes conjugados são apurados serem muito efetivos para combater infecções bacterianas causadas por bactérias gram-positivas e gram-negativas, incluindo as suas cepas resistentes. de modo significativo, também são efetivos em ambientes complexos, incluindo sangue,soro e outros fluidos corpóreos que estão presentes no corpo do paciente. é também provido um método de uso para controlar microorganismos patogênicos em pessoas humanas e animais.
BR112013001577-2A 2010-07-22 2011-07-22 conjugados de carboidrato e dihidroxiclorina BR112013001577B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36671810P 2010-07-22 2010-07-22
US61/366,718 2010-07-22
PCT/US2011/045063 WO2013015774A1 (en) 2011-07-22 2011-07-22 Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy

Publications (2)

Publication Number Publication Date
BR112013001577A2 true BR112013001577A2 (pt) 2017-12-12
BR112013001577B1 BR112013001577B1 (pt) 2021-05-04

Family

ID=47006517

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001577-2A BR112013001577B1 (pt) 2010-07-22 2011-07-22 conjugados de carboidrato e dihidroxiclorina

Country Status (7)

Country Link
US (1) US9308185B2 (pt)
EP (1) EP2616065B1 (pt)
CN (1) CN103096887B (pt)
BR (1) BR112013001577B1 (pt)
IL (1) IL224380A (pt)
MX (1) MX352281B (pt)
PL (1) PL2616065T3 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6041360B2 (ja) * 2011-07-22 2016-12-07 バイオリテック ウンターネーメンスベタイリグンクス ツヴァイ アクツィエンゲゼルシャフト 抗菌性光線力学療法のための、糖−置換ジヒドロキシ−クロリン及びβ−官能化クロリン
US9156849B2 (en) * 2011-08-12 2015-10-13 Biolitec Pharma Marketing Ltd Application of β-functionalized dihydroxy-chlorins for PDT
CN103285403B (zh) * 2013-06-21 2015-03-04 苏州大学 一种络合卟啉含糖光敏剂及其制备方法
EP3201201B1 (en) 2014-09-30 2022-01-26 biolitec unternehmensbeteiligungs II AG Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
CN108136196B (zh) 2015-07-28 2020-07-17 诺欧生物有限责任公司 用于对一氧化氮的光疗调节的系统和方法
EP3210626A1 (en) 2016-02-26 2017-08-30 biolitec Unternehmensbeteiligungs II AG Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
US20220025185A1 (en) 2018-12-10 2022-01-27 Universitat Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
US11986666B2 (en) 2020-03-19 2024-05-21 Know Bio, Llc Illumination devices for inducing biological effects
US12011611B2 (en) 2020-03-19 2024-06-18 Know Bio, Llc Illumination devices for inducing biological effects
US11147984B2 (en) 2020-03-19 2021-10-19 Know Bio, Llc Illumination devices for inducing biological effects
US11654294B2 (en) 2021-03-15 2023-05-23 Know Bio, Llc Intranasal illumination devices

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005025A (en) * 1959-08-07 1961-10-17 American Cyanamid Co Preparation of neutral chlortetracycline
FR2709491B1 (fr) * 1993-09-03 1995-10-27 Centre Nat Rech Scient Nouveaux dérivés de porphyrines et leurs applications notamment en thérapeutique.
EP1279676A1 (en) * 2001-07-19 2003-01-29 Institut Curie Porphyrin derivatives for photodynamic therapy
US7110533B2 (en) * 2004-05-18 2006-09-19 Time Warner Cable, Inc. Telephone NID isolation module
RU2574062C9 (ru) * 2008-09-18 2016-10-27 Биолитек Унтернеменсбетайлигунгс Ii Аг НОВЫЙ СПОСОБ И ПРИМЕНЕНИЕ НЕСИММЕТРИЧНО мезо-ЗАМЕЩЕННЫХ ПОРФИРИНОВ И ХЛОРИНОВ ДЛЯ ФДТ
BR112013001576A2 (pt) * 2010-07-22 2016-07-19 Ceramoptec Gmbh composto tetrapirrólico e composição farmacêutica derivado farmacêuticamente aceitável da mesma e respectivos usos e métodos de terapia fotodinâmica e de diagnóstico e tratamento da artrite e de doenças inflamatórias semelhantes.

Also Published As

Publication number Publication date
EP2616065B1 (en) 2017-11-01
PL2616065T3 (pl) 2018-05-30
BR112013001577B1 (pt) 2021-05-04
CN103096887A (zh) 2013-05-08
US20120263625A1 (en) 2012-10-18
EP2616065A1 (en) 2013-07-24
MX352281B (es) 2017-11-16
EP2616065A4 (en) 2014-05-14
MX2013000876A (es) 2013-04-30
IL224380A (en) 2017-06-29
CN103096887B (zh) 2017-12-29
US9308185B2 (en) 2016-04-12

Similar Documents

Publication Publication Date Title
BR112013001577A2 (pt) conjugados de carboidrato e dihidorxiclorina e clorina &lt;225&gt;-funcionalizada e respectivos usos e método para eliminar microorganismos em ambiente de paciente real
BR112013028813A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
BR112013000097A2 (pt) composições e métodos relacionados a variantes da proteína a (spa)
BR112014027818A2 (pt) prevenção, ruptura e tratamento do biofilme com a lisina bacteriófaga
NZ593111A (en) Antibacterial compounds
BR112013032974A2 (pt) &#34;derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas&#34;.
BR112015006568A2 (pt) composições e bactéria de ácido láctico
Ashkenazi Beginning and possibly the end of the antibiotic era.
BR112016006589A2 (pt) composição, e composição de vacina
MX2021008036A (es) Bioplaguicidas para la enfermedad tizon tardio de la papa.
ES2571998T3 (es) Composiciones y usos médicos de derivados del ajoeno
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
WO2008036761A8 (en) Anti-microbial defensin-related peptides and methods of use
EA201491272A1 (ru) Нанопродукт, содержащий lactobacillus reuteri dan080, подходящий для профилактики и терапии - человеческой и ветеринарной, и его медицинское применение
Zmantar et al. Modulation of drug resistance and biofilm formation of Staphylococcus aureus isolated from the oral cavity of Tunisian children
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
BR112014026861A2 (pt) antígenos de estafilococos coagulase e métodos de seu uso
WO2010125196A3 (en) Bacteriophages specific to pak and cha strains of pseudomonas aeruginosa and their applications
Litterio et al. Isolation of Serratia rubidaea from a mixed infection after a horse bite
Yang et al. Silver nanoparticles as a smart antimicrobial agent
CN102754666A (zh) 医疗机构物体表面草本消毒剂
WO2016066722A3 (en) Bacteriophage combinations for human or animal therapy
MX2009001074A (es) Terapia fotodinamica antimicrobiana.
BR112014005221A2 (pt) uso de materiais de fibra oca modificada para a remoção de exotoxinas produzidas por escherichia coli a partir de liquidos, de preferência a partir de sangue e de plasma, bem como seu uso para o tratamento de doenças concomitantes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.